During the past decade, BHI Inc conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "BHI Inc" are "ADHD" (1 trials) and "Attention Deficit Hyperactivity Disorder (ADHD)" (1 trials). Many other conditions were trialed in "BHI Inc" in a lesser frequency.

Most popular intervention types in "BHI Inc" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (1 trials), "SPD503 (Guanfacine hydrochloride)" (1 trials) and "Vyvanse (lisdexamfetamine dimesylate)" (1 trials). Other intervention names were less common.

The vast majority of trials in "BHI Inc" are 2 trials for "All" genders.

Currently, there are NaN active trials in "BHI Inc". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in BHI Inc, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in BHI Inc, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".